Gilead Sciences (NASDAQ:GILD) reported fourth-quarter earnings after the market close on Feb. 5 and the stock price fell 2% the following day. Although the company beat expectations at the top line, profits and earnings per share both disappointed, and guidance for 2020 underwhelmed investors.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,